Prime Medicine, Inc. (PRME) Investor Relations Documents

Prime Medicine, Inc. (PRME) investor relations documents from the company's IR site: 11 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-06	Press release	Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-23	Press release	Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson
2026-07-08	Press release	Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
2026-06-22	Press release	Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment o
2026-06-18	Press release	Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
2026-06-03	Press release	Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-28	Press release	Prime Medicine to Present at Jefferies Global Healthcare Conference
2026-05-07	Press release	Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-04-16	Press release	Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
2026-03-03	Press release	Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
2026-02-25	Press release	Prime Medicine to Participate in Upcoming Investor Conferences

PRME overview · PRME earnings · PRME financials · PRME KPIs · PRME ownership · PRME peers · PRME filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.